Bijal D. Shah, MD, of the H. Lee Moffitt Cancer Center, discusses key studies of CAR T-cell therapy in relapsed B-cell ALL and the adverse events that this treatment may cause.
Anne M. Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest recommendations for screening and diagnosing hepatocellular carcinoma, an aggressive tumor marked by increasing incid...
Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews promising experimental treatments, as well as PARP inhibitor therapy in TNBC, including the implications of newly approved ol...
William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses recent evidence on the efficacy, safety, and utility of HER2-targeted treatments in t...
Lee N. Newcomer, MD, who recently retired as Senior Vice President for Oncology and Genetics at UnitedHealth Group, discusses lessons learned during his long career in managed care, where we are, and ...
April K.S. Salama, MD, of Duke Cancer Institute, talks about how to select systemic therapy for a patient with previously treated metastatic melanoma.
James L. Mohler, MD, of Roswell Park Cancer Institute, discusses personalized medicine, molecular risk stratification, and better androgen-deprivation therapy for men with prostate cancer.
Alan P. Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses which biomarkers to order and when, the role of checkpoint inhibitors, and chemotherapy choices.
Ellin Berman, MD, of Memorial Sloan Kettering Cancer Center, discusses the effects of TKI therapy on fetal development, its impact on pregnancy outcomes, and how to develop an effective treatment plan...